|
|
Article: DUSA Pharmaceuticals Reports Third Quarter Corporate Highlights And Financial Results, Including:.
- Article from:
- Business Wire
- Article date:
- November 12, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
WILMINGTON, Md.--(BUSINESS WIRE)--Nov. 12, 2002
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA)
-- DUSA Completes Re-Acquisition of Levulan(R) PDT Dermatology Rights from Schering AG, Germany; Refocuses Dermatology Efforts on Expanding Labeling
-- Acceleration of Previous Schering AG Payments Leads to Non-Recurring $15.8 Million Profit During Third Quarter
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) reported today its corporate highlights and financial results for the third quarter ended September 30, 2002. The quarter's major event was the completion of the re-acquisition of Levulan PDT dermatology ...
Related newspaper, magazine, and journal articles:
|
|
Article: DUSA Pharmaceuticals Reports New CPT Code ...
Business Wire;
November 2, 2001 ;
700+ words
... ... Proposed By CMS (Formerly HCFA) DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA ... Laboratories, the US affiliate of Schering AG, Germany, (DUSA's Levulan ... submissions if appropriate. DUSA Pharmaceuticals, Inc. is a biopharmaceutical ...
|
|